Oncotelic Therapeutics (Oncotelic Therapeutics) Growth Rank : 0 (As of Apr. 27, 2024)

View and export this data going back to 1993. Start your Free Trial

What is Oncotelic Therapeutics Growth Rank?

Oncotelic Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Oncotelic Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Oncotelic Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncotelic Therapeutics (Oncotelic Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncotelic Therapeutics Inc (OTCPK:OTLC) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

29397 Agoura Road, Suite 107, Agoura Hills, CA, USA, 91301

Website

https://www.oncotelic.com

Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.

Executives

Vuong Trieu	officer: CHIEF EXECUTIVE OFFICER	4003 JIM BOWIE ROAD, AGOURA HILLS CA 91301
Saran Saund	officer: CHIEF BUSINESS OFFICER	C/O MATEON THERAPEUTICS INC., 29397 AGOURA RD SUTIE 107, AGOURA HILLS CA 91301
Amit B. Shah	officer: CHIEF FINANCIAL OFFICER	10 AGUILA, ALISO VIEJO CA 92656
Chulho Park	officer: CHIEF TECHNOLOGY OFFICER	701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Maida Anthony E Iii	director	157 TECHNOLOGY DR, IRVINE CA 92618
Steven W King	director
David Diamond	director	29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Fatih Uckun	10 percent owner, officer: Chief Medical Officer	701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Chao Hsiao	10 percent owner	701 GATEWAY BOULEVARD, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Larn Hwang	10 percent owner	C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Donald Rogers Reynolds	director	C/O WYRICK ROBBINS YATES & PONTON LLP, 4101 LAKE BOONE TRAIL, SUITE 300, RALEIGH NC 27607
Sandage Bobby W Phd	director	C/O 99 HAYDEN AVE, 1 LEDGEMONT CENTER, LEXINGTON MA 02173
Simon Pedder	director	1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Matthew M Loar	officer: Chief Financial Officer	505 PENOBSCOT DR, REDWOOD CITY CA 94063
Pamela Ha	officer: Controller	701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080